Learn about the impact of NASH and the interplay with diabetes, obesity, and cardiovascular disease.
Learn about the impact of NASH and the interplay with diabetes, obesity, and cardiovascular disease.
The pathogenesis of NASH is complex, but there’s insight in looking at diabetes, obesity, and insulin resistance through the lens of the liver.
Learn about who is at risk and who should be evaluated for progression to advanced fibrosis in NASH.
Learn about who is at risk and should be evaluated for progression to advanced fibrosis in NASH.
AASLD guidelines do not recommend routine screening for NAFLD or NASH, but they and other guidelines do call out patients with type 2 diabetes as warranting workup.
Learn how to use noninvasive tests to identify individuals with NAFLD and determine their risk of progression to NASH fibrosis.
Learn the best tools and approaches to identify NAFLD and to rule in or rule out NASH fibrosis.
With the many noninvasive tests available for screening those who are at risk for NAFLD/NASH, where should we begin and what is the optimal sequence of testing? Here’s my approach.
Hear expert insights on the roles of currently available approaches—and the most recent evidence—for managing NASH.
Learn the roles of currently available approaches—and the most recent evidence—for managing NASH.
There are no FDA-approved treatments for NASH. But there are still ways to manage it.
Hear expert insights on emerging approaches for managing NASH, targeting both hepatic and extrahepatic manifestations.
Hear expert perspectives on histologic and metabolic endpoints in NASH studies and how they may inform potential targets for oral, injectable, and combination NASH treatments.
My take on how emerging drugs are measuring up.
Expert recap of highlights from the NASH Core Curriculum, including pathogenesis, risk factors, and current and emerging therapies for patients with NAFLD/NASH.
Expert recap of highlights from the NASH Core Curriculum, including pathogenesis, risk factors, and current and emerging therapies for patients with NAFLD/NASH.
Easy-to-read reminders on why and how to look for NAFLD and NASH in your patients.
Download for your patients and their caregivers: patient-friendly overview of the impact of NASH, including its high prevalence and consequences, plus currently recommended approaches to NASH management.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.